Untimely timely: pimavanserin

Lane Simonian

I had just mentioned pimavanserin [Nuplazid] earlier today on another post for the potential use against psychosis in some forms of dementia, but had not seen the most recent news.

FDA Rejects Nuplazid to Treat Dementia-related Psychosis

These included the lack of significant benefits in some dementia forms and the small number of patients with less common subtypes, which led the agency to conclude evidence was insufficient to support Nuplazid’s approval for this indication at this point.

https://alzheimersnewstoday.com/2021/04/05/fda-rejects-nuplazid-acadia-dementia-related-psychosis-treatment/  

The decision and the results themselves are somewhat controversial.

One of these days, maybe there will be a drug whose results are clear-cut in terms of benefits.